LBPH Peter Lynch Chart
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Low P/E stocks
Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
Explore more intrinsic value tools hub for LBPH
FAQ
What is Longboard Pharmaceuticals, Inc. earnings per share (EPS)?
Longboard Pharmaceuticals, Inc. earnings per share (EPS) for the twelve months ending Mar 13, 2025 was N/A, a N/A increase year-over-year.
What is Longboard Pharmaceuticals, Inc. Price to Earnings (P/E) ratio?
As of Mar 13, 2025, Longboard Pharmaceuticals, Inc.'s P/E ratio is (30.6x). This is calculated by dividing the current share price of N/A by the Earnings per Share (EPS) for the trailing twelve months, which is N/A. The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.
Is Longboard Pharmaceuticals, Inc. overvalued or undervalued?
Longboard Pharmaceuticals, Inc. is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $11.2, compared to a market price of around $60.0. This suggests a potential overvaluation of 81.3%.